|

Anlotinib Clinical Trials

22 actively recruiting trials

▲ +1 trial since May 2026

Also known as: AL001, Adebrelimab, Anlotinib Hydrochloride Capsules, Anlotinib dihydrochloride, Anlotinib hydrochloride +2 more

Pipeline

Phase 1: 1Phase 2: 14Phase 3: 1Phase 4: 1Phase 1/2: 1Phase 2/3: 2

Top Sponsors

  • Fudan University5
  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences2
  • Zhongnan Hospital1
  • Zhejiang Cancer Hospital1
  • West China Hospital1

Indications

Other22 trials

A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy
Phase 2
A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults
Phase 2
A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
Phase 2/3
Anlotinib Combined With Doxorubicin and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma
Phase 4
Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer
Phase 2/3
Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.
Phase 3
Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer
Phase 1
Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer
Phase 2
Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy
Phase 2
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
Phase 2
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Phase 2
GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.
Phase 2
Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC
N/A
Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC
Phase 2
Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC
Phase 2
Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer
Phase 2
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
Phase 2
Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT
Phase 2
Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma
Phase 1/2
Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer
Phase 2
The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical Study
N/A
To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.